Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 22

PMID 33348908

Citations 36

Authors

Clarissa Berardo

Laura Giuseppina Di Pasqua

Marta Cagna

Plinio Richelmi

Mariapia Vairetti

Andrea Ferrigno

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a continuum of liver abnormalities often starting as simple steatosis and to potentially progress into nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma. Because of its increasing prevalence, NAFLD is becoming a major public health concern, in parallel with a worldwide increase in the recurrence rate of diabetes and metabolic syndrome. It has been estimated that NASH cirrhosis may surpass viral hepatitis C and become the leading indication for liver transplantation in the next decades. The broadening of the knowledge about NASH pathogenesis and progression is of pivotal importance for the discovery of new targeted and more effective therapies; aim of this review is to offer a comprehensive and updated overview on NAFLD and NASH pathogenesis, the most recommended treatments, drugs under development and new drug targets. The most relevant in vitro and in vivo models of NAFLD and NASH will be also reviewed, as well as the main molecular pathways involved in NAFLD and NASH development.

Citing Articles

Exploring the therapeutic potential of natural compounds against hepatocellular carcinoma (HCC): a computational approach.

Ilyas S, Manan A, Choi Y, Lee D EXCLI J. 2025; 23():1440-1458.

PMID: 39790561 PMC: 11713998. DOI: 10.17179/excli2024-7970.

Bioinformatics based exploration of the anti-NAFLD mechanism of Wang's empirical formula via TLR4/NF-κB/COX2 pathway.

Chen S, Zhou C, Huang J, Qiao Y, Wang N, Huang Y Mol Med. 2024; 30(1):278.

PMID: 39730994 PMC: 11673956. DOI: 10.1186/s10020-024-01022-3.

Myokines and Their Potential Protective Role Against Oxidative Stress in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Bucarey J, Trujillo-Gonzalez I, Paules E, Espinosa A Antioxidants (Basel). 2024; 13(11).

PMID: 39594505 PMC: 11591161. DOI: 10.3390/antiox13111363.

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.

Rabiu L, Zhang P, Afolabi L, Saliu M, Dabai S, Suleiman R J Gastroenterol. 2024; 59(12):1053-1078.

PMID: 39400718 DOI: 10.1007/s00535-024-02157-0.

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.

Zheng H, Sechi L, Navarese E, Casu G, Vidili G Cardiovasc Diabetol. 2024; 23(1):346.

PMID: 39342178 PMC: 11439309. DOI: 10.1186/s12933-024-02434-5.

References

Boga S, Alkim H, Koksal A, Bayram M, Ozguven M, Ergun M . Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. J Investig Med. 2015; 63(7):871-7. DOI: 10.1097/JIM.0000000000000230. View

Saklayen M . The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. PMC: 5866840. DOI: 10.1007/s11906-018-0812-z. View

Caldwell S . NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017; 23(2):103-108. PMC: 5497667. DOI: 10.3350/cmh.2017.0103. View

Pan M, Cederbaum A, Zhang Y, Ginsberg H, Williams K, Fisher E . Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest. 2004; 113(9):1277-87. PMC: 398425. DOI: 10.1172/JCI19197. View

Ip E, Farrell G, Hall P, Robertson G, Leclercq I . Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004; 39(5):1286-96. DOI: 10.1002/hep.20170. View

Knight B, Hebbachi A, Hauton D, Brown A, Wiggins D, Patel D . A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. Biochem J. 2005; 389(Pt 2):413-21. PMC: 1175119. DOI: 10.1042/BJ20041896. View

Solinas G, Boren J, Dulloo A . De novo lipogenesis in metabolic homeostasis: More friend than foe?. Mol Metab. 2015; 4(5):367-77. PMC: 4421107. DOI: 10.1016/j.molmet.2015.03.004. View

Xu P, Zhai Y, Wang J . The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. Int J Mol Sci. 2018; 19(4). PMC: 5979375. DOI: 10.3390/ijms19041260. View

Hollman D, Milona A, van Erpecum K, van Mil S . Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta. 2012; 1821(11):1443-52. DOI: 10.1016/j.bbalip.2012.07.004. View

10.

Khalil R, Khedr N . Curcumin Protects against Monosodium Glutamate Neurotoxicity and Decreasing NMDA2B and mGluR5 Expression in Rat Hippocampus. Neurosignals. 2016; 24(1):81-87. DOI: 10.1159/000442614. View

11.

Polyzos S, Kang E, Tsochatzis E, Kechagias S, Ekstedt M, Xanthakos S . Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism. 2020; 113:154413. DOI: 10.1016/j.metabol.2020.154413. View

12.

Santhekadur P, Kumar D, Sanyal A . Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2017; 68(2):230-237. PMC: 5775040. DOI: 10.1016/j.jhep.2017.10.031. View

13.

Neuschwander-Tetri B, Van Natta M, Tonascia J, Brunt E, Kleiner D . Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply. Lancet. 2015; 386(9988):28-29. DOI: 10.1016/S0140-6736(15)61200-4. View

14.

Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B . Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol. 2011; 92(6):413-21. PMC: 3248077. DOI: 10.1111/j.1365-2613.2011.00793.x. View

15.

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

16.

Feldstein A, Gores G . Steatohepatitis and apoptosis: therapeutic implications. Am J Gastroenterol. 2004; 99(9):1718-9. DOI: 10.1111/j.1572-0241.2004.40573.x. View

17.

Lamichane S, Dahal Lamichane B, Kwon S . Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis. Int J Mol Sci. 2018; 19(4). PMC: 5979443. DOI: 10.3390/ijms19040949. View

18.

Davidson M, Kukla D, Khetani S . Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integr Biol (Camb). 2017; 9(8):662-677. DOI: 10.1039/c7ib00027h. View

19.

Richir M, Bouwman R, Teerlink T, Siroen M, de Vries T, van Leeuwen P . The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008; 32(6):613-21. DOI: 10.1177/0148607108321702. View

20.

Marino L, Jornayvaz F . Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 21(39):11053-76. PMC: 4607905. DOI: 10.3748/wjg.v21.i39.11053. View